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The congenital muscular dystrophies (CMD) are a heterogeneous group of autosomal recessive disorders presenting
in infancy with muscle weakness, contractures, and dystrophic changes on skeletal-muscle biopsy. Structural brain
defects, with or without mental retardation, are additional features of several CMD syndromes. Approximately
40% of patients with CMD have a primary deficiency (MDC1A) of the laminin a2 chain of merosin (laminin-2)
due to mutations in the LAMA2 gene. In addition, a secondary deficiency of laminin a2 is apparent in some CMD
syndromes, including MDC1B, which is mapped to chromosome 1q42, and both muscle-eye-brain disease (MEB)
and Fukuyama CMD (FCMD), two forms with severe brain involvement. The FCMD gene encodes a protein of
unknown function, fukutin, though sequence analysis predicts it to be a phosphoryl-ligand transferase. Here we
identify the gene for a new member of the fukutin protein family (fukutin related protein [FKRP]), mapping to
human chromosome 19q13.3. We report the genomic organization of the FKRP gene and its pattern of tissue
expression. Mutations in the FKRP gene have been identified in seven families with CMD characterized by disease
onset in the first weeks of life and a severe phenotype with inability to walk, muscle hypertrophy, marked elevation
of serum creatine kinase, and normal brain structure and function. Affected individuals had a secondary deficiency
of laminin a2 expression. In addition, they had both a marked decrease in immunostaining of muscle a-dystroglycan
and a reduction in its molecular weight on western blot analysis. We suggest these abnormalities of a-dystroglycan
are caused by its defective glycosylation and are integral to the pathology seen in MDC1C.
Introduction
The congenital muscular dystrophies (CMD) are a het-
erogeneous group of autosomal recessively inherited dis-
eases, presenting at birth or within the first 6 mo of life
with hypotonia, muscle weakness, and the variable ap-
pearance of contractures and characterized by dys-
trophic changes on skeletal-muscle biopsy (Dubowitz
1995). The differing degrees of motor developmental
delay, physical disability, muscle pathology, and eleva-
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tion of serum creatine kinase (CK), along with the var-
iable presence of mental retardation and structural brain
defects, underscores the heterogeneous nature of this
condition. Recent epidemiological data suggest that the
incidence of CMD is and that its prevalence54.65# 10
is (Mostacciuolo et al. 1996), indicating that68# 10
it is among the most frequent autosomal recessively in-
herited neuromuscular diseases.
One of the main objectives of the International Con-
sortium on CMD has been to delineate and subdivide
the various forms of CMD (Dubowitz 1994, 1995,
1997, 1999; Muntoni et al., in press). Seven genetically
distinct entities have been identified so far. The most
common form of CMD (∼40% of cases) is due to a
primary deficiency in the laminin a2 chain of merosin
(laminin-2), resulting from mutations in the LAMA2
gene (MDC1A [MIM 156225]; Tome et al. 1994; Helb-
ing-Leclerc et al. 1995). Other CMD disease genes iden-
tified so far are ITGA7, leading to integrin a7 deficiency
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([MIM 600536]; Hayashi et al. 1998); COL6A2, cod-
ing for the a2 chain of collagen VI, in the Ullrich variant
(UCMD [MIM 254090]; Camacho Vanegas et al.
2001); and fukutin, responsible for Fukuyama congen-
ital muscular dystrophy (FCMD [MIM 253800], Fu-
kuyama et al. 1981; Kobayashi et al. 1998). Other
forms of CMD that have been mapped but for which
the disease genes remain elusive are muscle-eye-brain
disease (MEB [MIM 236670]), mapped to chromosome
1p32-34 (Cormand et al. 1999); a form with rigidity of
the spine (RSMD1 [MIM 602771]), mapped to 1p35-
36 (Moghadaszadeh et al. 1998); and a variant char-
acterized by muscle hypertrophy (MDC1B [MIM
604801]), mapped to 1q42 (Muntoni et al. 1998; Brock-
ington et al. 2000). The primary role of abnormalities
of the extracellular matrix in these diseases is exempli-
fied by the defects in genes for laminin a2, integrin a7,
and collagen VI. In addition, basal lamina abnormalities
have also been demonstrated in FCMD by means of
electron microscopy (Ishii et al. 1997).
Merosin consists of three laminin chains,a2b1g1,with
a2 forming a link between a-dystroglycan and the basal
lamina (Henry et al. 1999). a-dystroglycan is a heavily
glycosylated peripheral-membrane component of the
dystrophin-associated glycoprotein complex (DAPC),
which, in addition to laminin a2, binds perlecan and
agrin in the extracellularmatrix, whereasb-dystroglycan,
derived from the same gene (Holt et al. 2000), is a trans-
membrane protein that links to dystrophin intracellularly
(Ibraghimov-Beskrovnaya et al. 1992). Dystroglycan
therefore plays a pivotal role in linking the actin-asso-
ciated cytoskeleton to components of the extracellular
matrix (Ervasti et al. 1991; Ibraghimov-Beskrovnaya et
al. 1992), and disruption of this axis is associated with
several forms of muscular dystrophy (Campbell 1993).
FCMD is one of a number of CMD forms that have
been shown to have a secondary reduction in the ex-
pression of laminin a2 (Hayashi et al. 1993). Recently,
a profound depletion of skeletal and cardiac muscle a-
dystroglycan has also been reported in FCMD (Hayashi
et al. 2001). FCMD is common in Japan, because of a
founder haplotype containing a 3.0-kb retrotransposal
insertion into the 3′ UTR of the FCMD gene (Kobayashi
et al. 1998). Fukutin, a protein of unknown function,
is predicted to be a secreted protein that has sequence
similarities to a family of proteins involved in modifying
cell-surface molecules such as glycoproteins and gly-
colipids (Aravind et al. 1999). Fukutin also contains a
conserved DxD motif that is found in many glycosyl-
transferases (Aravind et al. 1999; Breton and Imberty
1999).
Although FCMD is rare outside Japan, other CMD
syndromes with secondary laminin a2 deficiency with
or without brain involvement are not, including
MDC1B (Brockington et al, 2000), MEB (Haltia et al.
1997), and other, as-yet-unmapped variants (Talim et
al. 2000; Villanova et al. 2000). We have used sequence
analysis to identify fukutin homologues in the human
genome as candidate genes for these variants of CMD.
In the present study, we report the identification of a
gene encoding a new member of the fukutin-related-pro-
tein family (FKRP [EMBL accession numberAJ314847]).
This gene is mutated in a severe form of CMD, which
we have called “MDC1C.” Patients harboringmutations
in this gene had a secondary deficiency of laminin a2
and a profound reduction in a-dystroglycan immunos-
taining. In addition, the molecular weight of a-dystro-
glycan was reduced in muscle. Together, these findings
suggest that this protein is abnormally glycosylated in
MDC1C and is central to the pathology seen in this
disorder.
Families, Material, and Methods
Family 1
We recently reported the clinical features of the two
children in this Scottish family and suggested that they
are affected by a novel form of CMD (Mercuri et al.
2000). Both children presented soon after birth with
hypotonia and feeding difficulties. They never acquired
the ability to walk, because of severe weakness, which
also affected their facial muscles. Weakness affected the
arms more than the legs, with prominent wasting of the
deltoids and pectoralis muscles, whereas both calf and
quadriceps muscles were hypertrophied. Cognitive de-
velopment, intelligence, and vision were normal, as was
brain magnetic resonance imaging. SerumCKwasmark-
edly elevated (9,000–14,550 IU/L, normal values !190
IU/liter). The older sibling died suddenly at age 7 years,
following an upper respiratory tract infection. The
younger sibling is now 4 years old and recently had a
gastrostomy because of feeding difficulties.
Family 2
This is a consanguineous family from Libya with one
affected child. In addition, two children on the paternal
side of the family had died in the first decade of life with
a similar illness. She presented in the first few weeks of
life with hypotonia and feeding difficulties, followed by
motor delay. On examination at age 16 mo, she could
not walk and was weaker in her arms than in her legs.
She had calf hypertrophy and facial weakness. Her se-
rum CK was 2,478 IU/liter and she had a myopathic
EMG. Her intelligence was normal.
Family 3
The affected child in this family is a 6.5-year-old girl
from southern England who is currently unable to stand
or walk. She presented with hypotonia in the first few
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weeks of life, followed by delayed motor milestones. She
could stand with support between the ages of 4 and 6
years. Her intelligence was normal, her serum CK was
markedly elevated, and she had a muscle biopsy at age
9 mo that was dystrophic. At age 6 years, she had
marked hypertrophy of the leg muscles with wasting and
weakness of shoulder-girdle muscles, particularly her
deltoid, pectoralis, and sternocleidomastoid muscles. Se-
rum CK was elevated (2,695 IU/liter). A brain MRI
showed normal results; an echocardiogram showed
mildly impaired left-ventricular function.
Family 4
The third child of this Sudanese consanguineous fam-
ily is affected. A detailed clinical description of this pa-
tient and those from families 5, 6, and 7 has recently
been submitted elsewhere (S. Quijano-Roy, L. Galan, A
Ferreiro, F. Cheliout-Heraut, F. Gray, M. Fardeau, A.
Barois, P. Guicheney, N. B. Romero, and B. Estournet,
unpublished data). He presented at birth with hypo-
tonia, and his motor development was severely delayed;
he never acquired the ability to walk. Calf and tongue
hypertrophy were noticed at the ages of 4 and 10 years,
respectively. At age 14 years, he went into respiratory
failure and has been ventilated via a tracheostomy ever
since. His cognitive development and brain MRI were
normal; he developed a transient cardiac insufficiency
after a respiratory infection at age 11 years, but current
cardiac function is normal. Serum CK was elevated
(2,277 IU/liter) at age 10 years. He underwent three
muscle biopsies (at the ages of 2, 3, and 9 years) that
showed a dystrophic picture with normal expression of
dystrophin and sarcoglycans.
Laminin a2 expression was reduced with an antibody
against the 80-kDa fragment and was absent with an
antibody against the 300-kDa fragment. No muscle was
available to study the expression of a-dystroglycan.
Family 5
The only child from this nonconsanguineous family
of Caribbean origin is affected. She was symptomatic at
birth with weakness and hypotonia, and her motor de-
velopment was severely delayed. She could walk only
with assistance between the ages of 3 and 6 years. Hy-
pertrophy of the calves had been noticed in infancy, and
macroglossia appeared around puberty. She developed
progressive contractures in the elbows, knees, and fin-
gers. Her cardiac function was normal; however, she
developed restrictive respiratory insufficiency leading to
nasal ventilation at age 14 years and tracheostomy at
age 17 years. Spinal surgery was performed at age 16
years because of progressive scoliosis. Her serum CK
was 7,760 IU/liter at age 5 years. She underwent three
muscle biopsies (at the ages of 14 mo, 8 years, and 19
years) that showed a dystrophic picture with normal
expression of dystrophin and sarcoglycans. Laminin a2
expression was reduced with an antibody against the
80-kDa fragment and was almost absent with an anti-
body against the 300-kDa fragment. a-dystroglycan ex-
pression was virtually absent in her muscle. Her brain
MRI and mental function were normal.
Family 6
This is a 25-year-old patient, who was the first child
of a nonconsanguineous French couple. She presented
at birth with hypotonia, followed by delayed motor
milestones. She could stand with support between the
ages of 17 mo and 7 years; hypertrophy of her calves
was noticed at age 6 mo, and hypertrophy of her tongue
was noticed in her second decade of life. This eventually
required a partial glossectomy at age 23 years because
of progressive difficulties in chewing and swallowing.
Intelligence was normal. A serum CK at age 2 years was
markedly elevated. A brain MRI was normal, but a mild
impairment of her cardiac left-ventricular function was
documented on echocardiography at age 14 years. She
has been ventilated with a tracheostomy since age 13
years. A muscle biopsy showed a reduction of laminin
a2 with an antibody that recognizes the 80-kDa frag-
ment. No muscle was available to study the expression
of a-dystroglycan.
Family 7
The patient in this French family died at age 10 years
because of respiratory complications. She presented at
birth with hypotonia and delayed motor milestones; she
never acquired the ability to walk. Marked hypertrophy
of the calves and tongue was noticed in the first years
of life. Progressive feeding difficulties led to a gastros-
tomy at age 9 years; her intelligence and brainMRI were
normal, but echocardiography showed that her left-ven-
tricular function was at the lower limit of normal at age
9 years. She died shortly afterward because of respira-
tory complications. Laminin a2 was reduced with an
antibody that recognizes the 80-kDa fragment. There
was no muscle to study the expression ofa-dystroglycan.
Database Screening
We performed BLAST analysis for new fukutin hom-
ologues, using the BLAST server at NCBI. The identifi-
cation of transcribed sequences (ESTs) and their genomic
location was also performed using BLAST analysis. Se-
quence alignments were obtained using the ClustalW Ser-
vice at the European Bioinformatics Institute.
Northern Blot Analysis
We determined the expression of FKRP and an estimate
of transcript size by northern blot analysis using a blot
containing poly(A)RNA isolated from eight tissues (Hu-
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Figure 2 Schematic representation of the FKRP gene. The gene consists of 4 exons and spans no more than 12 kb. The entire coding
sequence is located within exon 4. The 5′ UTR is blackened, the FKRP open reading frame is unblackened, and the 3′ UTR is hatched.
Figure 1 Sequence of the human FKRP cDNA and analysis of the primary sequence. A, Partial nucleotide sequence and open reading
frame are shown. The 4-kb cDNA encodes a protein of 495 amino acids, with a predicted molecular weight of 54.6 kDa. B,Multiple sequence
alignment of fukutin homologues. Missense and nonsense mutations that were found to occur within the region aligned are indicated by red
asterisks (*) and slashes (/), respectively. Amino acid residues are colored according to an 80% consensus: plus signs () indicate positively
charged residues (H, K, and R; blue), minus signs () indicate negatively charged residues (D and E; red), black asterisks indicate serine or
threonine residues (light blue on grey background), “a” indicates aromatic residues (F, H, W, and Y; blue on yellow background), “b” indicates
big residues (E, F, H, I, K, L, M, Q, R, W, and Y; blue on yellow background), “c” indicates charged residues (DEHKR; pink), “h” indicates
hydrophobic residues (A, C, F, G, H, I, L, M, T, V, W, and Y; black on yellow background), “l” indicates aliphatic residues (I, L, and V; grey
on yellow), “p” indicates polar residues (C, D, E, H, K, N, Q, R, S, and T; blue), and s indicates small residues (A, C, D, G, N, P, S, T, and
V; green). Residues that are conserved in 180% of sequences are shown as yellow on black. Residues excised from the alignment are indicated
by numbers in parentheses. Predicted secondary structures are indicated below the alignment (e/E, extended or b-strand structure; h/H, helix).
Residue numbers and GeneInfo identifiers (or else cosmid names) are shown following the alignment. Ca p Candida albicans; Ce p Caenor-
habditis elegans; Dm p Drosophila melanogaster; HELP1 p haemolysin erythrocyte lysis protein 1; Hi p Haemophilus influenzae; Hs p
Homo sapiens; Llp Lactobacillus lactis lactis; Pi p Prevotella intermedia; Rpp Rickettsia prowazekii; Scp Saccharomyces cerevisiae; Spp
Streptococcus pyogenes; Tb p Trypanosoma brucei. Fukutin homologues partially encoded by ESTs in T. brucei (EST AQ655742), T.
cruzi(AI077222), and Leishmania major (AQ852136), as well as a Bacillus subtilis sequence similar to L. lactis TrpF C-terminal domain
(GeneInfo number 1750106; bases 12108–12419), are not shown. Two C. elegans sequences, marked with a dagger (†), are alternative gene
predictions that differ from published versions by the prediction of additional exons.
man Multiple Tissue northern blot I, Clontech). An 836-
bp DNA probe containing bp 253–1088 of the FKRP
coding sequence was amplified with primers FKRP-2F
(GAGCTGGTAGACTCCTTCCT) and FKRP-4R (CCT-
TCTCCCATACGAAGC). The blot was hybridized with
the radiolabeled (32P) probe in ExpressHyb hybridization
solution (Clontech), according to the manufacturer’s
instructions.
Radiation Hybrid Mapping
The Genebridge 4 Radiation Hybrid DNA panel (UK-
MRC HGMP Resource Centre) and primers FKRP-2F
and FKRP-4R, amplifying a 836-bp fragment of FKRP,
were used to define the chromosomal localization of
FKRP. LOD scores were calculated using the RHyME
program on the UK-MRC HGMP Resource Centre Web
site.
Genotyping
Genomic DNA was extracted from whole blood by
standard methods. Linkage to the FKRP locus was as-
sessed by genotyping subjects for the dinucleotide repeat
markers D19S219 and D19S606. Genotyping was per-
formed using an ABI 377 Automated sequencer and was
analyzed using Genescan 3.1 and Genotyper 2.0 (Ap-
plied Biosystems).
Mutational Analysis
A 1.7-kb fragment containing the FKRP coding se-
quence was amplified using Advantage-GC Genomic
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Figure 3 Northern blot analysis demonstrating the expression
of FKRP mRNA. A 4.0-kb transcript is seen in all tissues studied. H
p heart; B p brain; Pl p placenta; Lg p lung; Lv p liver; SM p
skeletal muscle; Kp kidney; Pcp pancreas. It is most highly expressed
in skeletal muscle, placenta, and heart and is expressed relatively
weakly in the remaining tissues. An additional transcript of ∼3.6 kb
is visible in skeletal muscle, kidney, heart, and lung.
Polymerase Mix (Clontech) and primers FKRP-1F (AAA-
GGGAATTGAGAAAGAGC) and FKRP-5 (GCTCACA-
CAGAGCTTCTCC). PCR products were separated by
agarose gel electrophoresis, were purified (Qiagen), and
were used for direct sequencing. Sequencing reactions
were performed using a ABI Prism BigDye Terminator
Cycle Sequencing kit (Applied Biosystems) and primers
FKRP-1R (GCAGGAAGGAGTCTACCAG), FKRP-2R
(CCGAGAGGTTGAAGAGGT), FKRP-3R (CTCCTCG-
TAGAGGTAGGC), FKRP-4R, and FKRP-5R. Sequenc-
ing products were separated on an ABI377 automated
sequencer (Applied Biosystems) and analyzed using SeqEd
(Applied Biosystems).
Immunohistochemistry
Unfixed frozen 8-mm sections were incubated with
monoclonal antibodies to b-spectrin; lamininsa2, b1, and
g1 (Chemicon); a- and d-sarcoglycan (Novocastra); per-
lecan (Chemicon); and a-dystroglycan (V1A4-1 Upstate
Biotechnology). All primary antibodies were applied for
1 h and were revealed with an appropriate biotinylated
secondary antibody (Amersham 1:200) for 30 min, fol-
lowed by streptavidin conjugated to Alexa (Molecular
Probes) for 20 min. All dilutions and washings weremade
in phosphate buffered saline. Sections were mounted in
aqueous mountant and were viewed with epifluorescence
using a Leica Aristoplan microscope.
Immunoblotting
Muscle proteins were extracted in sample buffer con-
sisting of 1 M Tris HCl, 1% SDS, glycerol, 2-mercap-
toethanol, plus a cocktail of protease inhibitors (anti-
pain, aprotinin, and leupeptin). Soluble protein was
resolved using a NuPage Pre-cast gel (4%–12% Bis-Tris;
Invitrogen) and then was transferred electrophoretically
to nitrocellulose membrane (Sartorius). Nitrocellulose
strips were blocked in 5% milk powder in Tris-buffered
saline buffer; were probed with antibodies to a-dystro-
glycan (V1A4 1:1,000), b-dystroglycan (Novocastra 1:
25), and a- and g-sarcoglycan (Novocastra 1:50, 1:
100); and were washed and incubated with HRP-anti-
mouse (1:50,000; Jackson). Membranes were visualized
using chemiluminescence (ECLPlus, Amersham).
Results
Database Screening
Comparison of the mouse fukutin sequence with se-
quence databases using TBLASTN (Altschul et al. 1997)
revealed a murine expressed sequence tag (EST;
AA016785) that showed significant similarity (Ep
) across the proposed fukutin active-site region.38# 10
Reciprocal BLAST searches using a corrected version of
this sequence as a query demonstrated its significance to
fukutin homologues (Aravind and Koonin 1999), in par-
ticular Rickettsia prowazekii RP689 ( )5Ep 2# 10
and putative orthologous sequences in Homo sapiens
and Drosophila melanogaster (fig. 1b). The human ver-
sion of this sequence was determined by a combination
of EST assembly, reverse transcriptase PCR, and RACE
(fig. 1a). The cDNA has a 1,488-bp open-reading frame
that encodes a 495-amino-acid protein, which we have
called fukutin-related protein (fig. 1a). Sequence analysis
of FKRP predicts the presence of a hydrophobic trans-
membrane-spanning region (amino acids 4–28) followed
by a “stem region” and the putative catalytic domain.
A similar molecular organization is found in several
Golgi-resident glycosyltransferases (Munro 1998).
Radiation-Hybrid Mapping
Radiation-hybrid mapping using the Genebridge 4
Hybridization DNA panel gave a maximum two-point
LOD score of 17.25 with marker D19S219. The most
likely order of markers is centromere-D19S219-FKRP-
D19S606-telomere on chromosome 19q13.3. D19S219
and D19S606 are placed 3 cM apart on the Ge´ne´thon
map.
Genomic Organization and Northern Blot Analysis
The genomic organization of the FKRP gene was de-
termined by comparing the cDNA sequence with a con-
tiguous segment of chromosome 19 in contig NT-
011166.2. The 12-kb gene is composed of three
noncoding exons and a single large exon of 3.8-kb that
contains part of the 5′ untranslated region and the entire
open frame and 3′ untranslated region (fig. 2). Northern
blot analysis demonstrated a transcript of ∼4.0-kb in all
tissues studied. The FKRP transcript is expressed pre-
dominantly in skeletal muscle, placenta, and heart and
relatively weakly in the remaining tissues (fig. 3). An
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Figure 4 An example of mutation analysis in FKRP. a, The pedigree of family 1, showing the segregation of two heterozygous mutations,
A926G and C1154A. Both affected children are compound heterozygotes, whereas the unaffected sib has inherited only one of the at-risk
alleles. The father unexpectedly did not have the C1154A mutation in his lymphocyte DNA and most likely is a germline mosaic. Haplotype
analysis at this and other loci confirmed paternity (data not shown). b, DNA sequence analysis of FKRP, identifying the mutations in family
1.
additional transcript of ∼3.6 kb was visible in skeletal
muscle, kidney, and lung.
Mutation Analysis of the FKRP Gene
We initially studied the FKRP gene in 25 families with
CMD with brain involvement. No family’s results were
consistent with linkage to the FKRP locus. In addition,
direct sequencing of the FKRP coding region in nonin-
formative families showed that it was normal. We con-
cluded that FKRP was not a major locus for these dis-
orders, at least in our patient population.
Next, we looked at families with CMD with a sec-
ondary deficiency in laminin a2 and no brain involve-
ment. In seven families that shared a common, severe
phenotype, we identified mutations in the coding region
of FKRP that are expected to affect protein function (fig.
4 and table 1). In brief, we identified 10 different mu-
tations—8 missense and 2 nonsense. Both affected chil-
dren from consanguineous families 2 and 4 had ho-
mozygous missense changes, as did the affected child
from nonconsanguineous family 5. The affected children
in the remaining four families were compound hetero-
zygotes. Families 1 and 3 had one missense and one
frameshift mutation, whereas families 6 and 7 had two
missense mutations (table 1). In family 1, the C1154A
change was present in the mother, but the A926G change
was unexpectedly not found in the father’s lymphocyte
DNA, suggesting a germline mutation (fig. 4). The
changes were considered to be pathogenic, because they
segregated with the disease in a recessive fashion and
were not present in 100 control chromosomes. A small
number of silent changes were identified and are listed
in table 1.
Muscle Biopsy: Immunohistochemistry and
Immunoblot Analysis
The skeletal muscle biopsies showed a severe dys-
trophic picture in all cases (a haematoxylin- and eosin-
stained section from families 1 and 2 is shown in fig.
5a–b). Antibodies to a- and b-dystroglycan in families
1 and 2 showed preserved b-dystroglycan (fig. 5e–f) but
a severe depletion of a-dystroglycan on most fibers in
family 1 (fig. 5c), whereas 150% of fibers showed a
reduction in family 2 (fig. 5d). Only the muscle from
family 1 showed reduced labeling for laminin a2 (fig.
5g), b1, and g1, and this tended to be on the larger
rather than smaller fibers. In this family, only a minority
of fibers with a severe depletion of a-dystroglycan were
also associated with a reduction in laminin a2, b1, and
g1 labeling. However, the muscle from family 2 did not
Brockington et al.: Mutations in FKRP Cause a Form of CMD 1205
Table 1
Mutations and Polymorphisms Found in the FKRP
Gene
Change Inheritance
Protein
Effect
Mutations:
Family 1 (British):
A926G Heterozygous Tyr309Cys
C1154A Heterozygous Ser385Stop
Family 2 (Libyan):
C1378T Homozygous Pro448Leu
Family 3 (British):
G1016A Heterozygous Arg339His
165InsGGAG Heterozygous Asp60Stop
Family 4 (Sudanese):
C649A Homozygous Pro217Thr
Family 5 (Caribbean):
A1394C Homozygous Tyr465Ser
Family 6 (French):
C341G Heterozygous Ala114Gly
G1201A Heterozygous Asp401Asn
Family 7 (French):
C947G Heterozygous Pro316Arg
T983C Heterozygous Tyr328Ser
Polymorphisms:
C-34T Heterozygous None
C63A Heterozygous None
C135T Heterozygous None
C249T Heterozygous None
G648A Heterozygous None
G654A Heterozygous None
G1341A Heterozygous None
show any reduction in laminin a2 (fig. 5h), b1, and g1
labeling, suggesting that the absence of a-dystroglycan
in a large proportion of fibers is not directly associated
with a reduction in these laminin chains. Immunolabel-
ing of the membrane-associated proteins b spectrin and
dystrophin, along with the glycosylated proteins a- and
d-sarcoglycan, were within normal limits. Perlecan im-
munolabeling in families 1 and 2 was indistinguishable
from controls. A marked reduction in a-dystroglycan
expression was reported in two of our patients from
France, the only other families from which muscle was
available.
Immunoblot analysis of a-dystroglycan in families 1
and 2, adult control muscle, and Duchenne muscular
dystrophy (DMD) muscle was performed. A broad band
of ∼156 kDa was seen in normal muscle that was re-
active with antibody V1A4-1, which recognizes a gly-
cosylated epitope (fig. 6a). Families 1 and 2 showed a
narrowing of the broad reactive band with a marked
shift towards a lower molecular weight. Only minor al-
terations in the molecular weight of a-dystroglycanwere
apparent in the DMD muscle, despite the presence of a
similar number of immature fibers toMDC1C, as judged
by the expression of neonatal myosin (not shown). Both
MDC1C muscles showed the same abnormality in a-
dystroglycan on western blot. This suggests that the re-
duction in the mean a-dystroglycan molecular weight
observed in MDC1C was not simply a reflection of an
immature muscle but likely reflects differences in the
pattern of glycosylation in these MDC1C patients. The
reduction in b-dystroglycan in DMD was expected,
given the absence of dystrophin in these patients. The
molecular weight of the heavily glycosylated membrane
proteins a- and g-sarcoglycan, along with b-dystrogly-
can, were normal (figs. 6a–b).
Discussion
We have identified a new member of the fukutin family
of proteins, FKRP, whose gene maps to chromosome
19q13.3. FKRP, like fukutin, contains sequence motifs
identifying it as a putative sugar transferase (Aravind
and Koonin 1999; Breton and Imberty 1999).Mutations
in this gene give rise to a very distinct form of congenital
muscular dystrophy, which previously has been recog-
nized as a separate clinical entity (Mercuri et al. 2000;
S. Quijano-Roy, L. Galan, A Ferreiro, F. Cheliout-Her-
aut, F. Gray, M. Fardeau, A. Barois, P. Guicheney, N. B.
Romero, and B. Estournet, unpublished data). The char-
acteristic clinical features of this condition are onset in
the first few weeks of life; severe weakness and wasting
of the shoulder-girdle muscles; hypertrophy and weak-
ness of the leg muscles, with inability to walk; calf and
thigh hypertrophy; and severe restrictive respiratory in-
volvement, leading to respiratory failure in the second
decade of life. Several patients had signs of heart in-
volvement, and this suggests that cardiac muscle is also
affected in this disorder. Other invariable features were
preserved intelligence, normal brain structure on imag-
ing, and marked elevation of serum CK. A secondary
reduction in laminin a2 was also observed, although this
was less clear in some patients because of the severe
generalized muscle damage secondary to the dystrophic
muscle process. In keeping with established nomencla-
ture, we have called this disease “MDC1C” (MDC1A
represents CMD with a primary laminin a2 deficiency;
MDC1B has a secondary laminin a2 deficiency and calf
hypertrophy linked to 1q42). We did not observe pa-
tients with two null mutations in FKRP, a finding par-
alleled in FCMD, where it has been suggested that the
presence of two such mutations would be embryonic
lethal (Kondo-Iida et al. 1999).
Patients with MDC1C had a severe reduction in a-
dystroglycan immunolabeling that was much more dra-
matic than the reduction in laminin a2, the only ad-
ditional protein in which we could detect an altered
pattern of expression. The muscle biopsy from family
1 showed that fibers deficient in laminin a2 were also
deficient in a-dystroglycan immunolabeling, but the
converse was not true. This suggests that whatever re-
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Figure 5 Muscle sections, from families 1 (a) and 2 (b), stained with haematoxylin and eosin. Immunolabeling for a- and b-dystroglycan
is shown in c and e, repectively (family 1), and in d and f, respectively (family 2). a-dystroglycan was markedly reduced on most fibers in
family 1, whereas 150% of fibers showed a reduction in family 2. b-dystroglycan was normally expressed in all fibers in both families.
Immunolabeling for laminin a2 is shown in g (family 1) and h (family 2). A reduction in laminin a2 expression on the larger fibers was evident
only in family 1. Bar p 100 mm.
lationship exists between the reduction in a-dystrogly-
can and laminin a2, the deficiency in a-dystroglycan
occurs first. Perlecan expression was within normal lim-
its in families 1 and 2, suggesting that other components
of the basement membrane are not grossly perturbed.
The normal immunolabeling of b spectrin and dystro-
phin confirmed that the alterations in a-dystroglycan
were not due to generalized membrane damage, which
is often a feature of dystrophic muscle. These obser-
vations, together with the reduction in the average
weight of a-dystroglycan, raise the possibility that
FKRP is involved in the glycosylation of a-dystroglycan.
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Figure 6 a, Immunoblot analysis of muscle proteins extracted
from families 1 and 2 (F1 and F2) showed a marked shift in the average
molecular weight of a- but not b-dystroglycan. Control adult muscle
(CTRL), together with muscle from patients with Duchenne muscular
dystrophy (DMD), are included for comparison. The significant re-
duction in a-dystroglycan molecular weight was only observed in pa-
tients with MDC1C. b, The molecular weights of a- and g-sarcoglycan
are comparable with those of control and DMD muscle.
The normal expression of the glycosylated proteins a-
and g-sarcoglycan suggests that the pathogenesis of this
disorder is closely linked to the altered expression of a-
dystroglycan, rather than a more generalized effect on
glycosylated membrane proteins.
Dystroglycan is widely expressed, but its glycosyla-
tion pattern varies in a tissue-specific and developmental
pattern (Henry and Campbell 1999; Leschziner et al.
2000), and this may provide a possible mechanism by
which defects in individual glycosyltransferases can re-
sult in a tissue-specific phenotype. Many of a-dystro-
glycan’s binding partners, including laminin a2, rec-
ognize carbohydrate moieties, and their disruption
would be expected to have a profound effect on its
function (Durbeej et al. 1998; Montanaro et al. 1999).
This is supported by the recent finding that the gene
mutated in the recessive myodystrophy (myd) mouse
encodes a glycosyltransferase, LARGE, and results in
the altered glycosylation of a-dystroglycan (Grewal et
al. 2001). The myd mouse carries an out-of-frame de-
letion in the LARGE gene that is predicted to give rise
to a truncated protein lacking either of its two catalytic
domains, in effect creating a functional “knockout.”
Themyd phenotype is characterized by proximal muscle
weakness, reduced life span, elevated serum creatine ki-
nase, and a skeletal-muscle pathology with foci of de-
generation and regeneration. These features are shared
by MDC1C; however, the myd mouse also shows signs
of CNS involvement (sensorineural deafness) that is not
apparent inMDC1C (Mathews et al. 1995). In addition,
patients with MDC1C have a variable cardiac involve-
ment not seen in the myd mouse. Skeletal-muscle a-
dystroglycan expression in the myd mouse was found
to be virtually absent, using the same antibody as was
used in the present study. Because this antibody rec-
ognizes a glycosylated epitope, these observations sug-
gest that an abnormality in the glycosylation of dystro-
glycan may underlie the skeletal-muscle pathology seen
in this animal. However, no further comparisons can be
made, because data were not presented on the immu-
nohistochemical expression of either a-dystroglycan or
laminin a2 (Grewal et al. 2001), and the depletion of
a-dystroglycan on immunoblotting was more marked
than that observed in MDC1C. The skeletal muscle
from patients with FCMD also shows a severe immu-
nohistochemical reduction of a-dystroglycan and al-
most undetectable levels of a- but not b-dystroglycan,
when tested by immunoblotting. The biosynthesis of
glycoproteins is a complex pathway involving the con-
trolled activity of many different enzymes in the syn-
thesis of a variety of carbohydrate structures. It is prob-
able that FKRP, like fukutin and LARGE, participates
somewhere along one or more of these pathways in the
processing of a-dystroglycan. The more severe reduc-
tion of a-dystroglycan seen in both FCMD and the myd
mouse, compared with that seen in MDC1C, probably
represents the differing involvement of the respective
glycosyltransferase in the synthesis of the glycosylated
epitope recognized by the V1A4-1 antibody.
The altered processing of a-dystroglycan in MDC1C,
like FCMD and the myd mouse, is likely to be integral
to the pathology in this disease. However, although we
could find no evidence of other abnormalities in the
processing of other proteins, such as b-dystroglycan and
a- and g-sarcoglycan, the activities of glycosyltransfer-
ases are known to be permissive, and the existence of
additional substrates and the contribution to the pa-
thology that their altered processing would produce
cannot be ignored.
The altered processing of a-dystroglycan due to its
abnormal glycosylation in MDC1C, together with the
recent corresponding findings in FCMD and the myd
mouse, identifies a novel pathogenic mechanism in mus-
cular dystrophy and opens a new avenue of research
into these diseases.
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